Amgen (FRA:AMG) Cash Flow for Dividends: €-4,472 Mil (TTM As of Mar. 2026)


FRA:AMG Amgen Inc FRA:AMG
87 GF Score
Price €313.15
GF Value €308.97
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Amgen Cash Flow for Dividends?

Amgen FRA:AMG +2.20% 87 Cash Flow for Dividends is €-4,472 Mil as of Mar. 2026. GuruFocus rates FRA:AMG with a GF Score™ of 87/100 and a GF Value™ of €308.97 (Fairly Valued). The stock has 7 warning signs investors should review.

Amgen's cash flow for dividends for the three months ended in Mar. 2026 was €-1,175 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was €-4,472 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Amgen's quarterly payment of dividends increased from Sep. 2025 (€-1,092 Mil) to Dec. 2025 (€-1,096 Mil) and increased from Dec. 2025 (€-1,096 Mil) to Mar. 2026 (€-1,175 Mil).

Amgen's annual payment of dividends increased from Dec. 2023 (€-4,178 Mil) to Dec. 2024 (€-4,615 Mil) but then declined from Dec. 2024 (€-4,615 Mil) to Dec. 2025 (€-4,376 Mil).

Amgen Cash Flow for Dividends Related Terms

Amgen Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Amgen's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amgen Cash Flow for Dividends Chart

Amgen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3,551.51 -3,961.02 -4,177.85 -4,614.56 -4,375.90

Amgen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,183.08 -1,109.76 -1,092.26 -1,095.68 -1,174.67
FRA:AMG
87GF Score
Amgen Inc FRA:AMG
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amgen Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4,472 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of €-4,472 Mil mean?
Amgen (FRA:AMG) has a Cash Flow for Dividends of €-4,472 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Amgen and its competitors.
Is Amgen's Cash Flow for Dividends too high?
Amgen's current Cash Flow for Dividends is €-4,472 Mil. Overall, Amgen has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amgen's Cash Flow for Dividends compare to GILD and PFE?
Amgen's Cash Flow for Dividends of €-4,472 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Drug Manufacturers company?
A good Cash Flow for Dividends depends on the Drug Manufacturers industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Amgen and its competitors. Amgen's current Cash Flow for Dividends is €-4,472 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (FRA:AMG) is currently considered Fairly Valued. The stock's GF Value™ is €308.97, compared to a current price of €313.15 — trading 1.4% above its estimated fair value. The current Cash Flow for Dividends is €-4,472 Mil. Amgen's overall GF Score™ is 87/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Amgen (FRA:AMG), the current Cash Flow for Dividends is €-4,472 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amgen (FRA:AMG) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be overvalued. The current stock price of €313.15 is trading 1.4% above its estimated GF Value™ of €308.97. GuruFocus considers Amgen to be Fairly Valued.

Key valuation signals for FRA:AMG:

  • Cash Flow for Dividends: €-4,472 Mil
  • GF Value™: €308.97 vs. price of €313.15 (1.4% above fair value)
  • GF Score™: 87/100 with 7 warning signs

No single metric tells the full story. See the FRA:AMG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
87GF Score

Get the complete analysis for FRA:AMG

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€313.15
Price
€308.97
GF Value